DNA Aptamer Targeting HPV16 Tumor Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for HPV16-positive tumor cells face challenges such as resistance to chemotherapy, metastasis, and ineffective drug delivery, with a need for targeted compositions that can specifically bind and treat these cells for early detection and therapy.
Innovation Solution
Development of DNA aptamers with specific sequences (SEQ ID NO: 1 and SEQ ID NO: 2) that bind to HPV16-positive tumor cells, conjugated with diagnostic or therapeutic tags, allowing for targeted detection and therapy through methods like magnetic hyperthermia or photodynamic therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (chemotherapy, radiation therapy) are used for HPV16-positive tumor cells, then treatment coverage is broad, but resistance to chemotherapy drugs and metastasis occur
Solution Approach 1:
The patent uses aptamers as intermediary molecules that specifically bind to HPV16-positive tumor cells. These aptamers serve as mediators between the diagnostic/therapeutic system and the target cells, enabling selective recognition and binding without affecting normal cells. This resolves the contradiction by providing targeted action that avoids the harmful side effects of conventional broad-spectrum treatments.
Solution Approach 2:
The invention applies local quality by creating treatments with different properties for different cell types. The aptamers are designed to have high affinity specifically for HPV16-positive tumor cells while showing no binding to normal cells or HPV-negative cells. This localized specificity allows effective treatment of target cells without causing the resistance and metastasis problems associated with conventional chemotherapy.
2Measurement precision
If targeted substances are developed for molecular diagnosis or treatment, then diagnosis and treatment improvement is achieved, but inability to cross biological barriers and poor drug delivery remain
Solution Approach 1:
The aptamers are designed with multi-functionality, serving both as diagnostic agents and as vehicles for drug delivery. The same aptamer that provides precise binding to HPV16-positive cells can also carry therapeutic payloads across biological barriers. This universal design resolves the contradiction by combining high measurement precision with effective drug delivery capability in a single molecular entity.
3Reliability
If DNA aptamers are used for targeting HPV16-positive tumor cells, then high specificity and affinity are achieved, but production and conjugation complexity increases
Solution Approach 1:
The patent uses DNA aptamers that can be synthesized in large quantities through PCR amplification and other molecular biology techniques. This copying approach allows production of identical aptamer sequences with high fidelity, maintaining binding specificity while enabling scalable production. The genetic information can be replicated many times, providing a simple and efficient production method compared to protein-based alternatives.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DNA aptamers demonstrate high affinity and specificity for HPV16-positive cells, enabling effective detection and treatment by binding to surface proteins, overcoming limitations in existing cancer therapies.
Implementation Method 1
The DNA aptamers demonstrate high affinity and specificity for HPV16-positive cells, enabling effective detection and treatment by binding to surface proteins
Data Source
AI summary
A composition for binding to human papillomavirus type 16 (HPV16)-positive tumor cells, the composition including a DNA aptamer. The DNA aptamer includes one of SEQ ID NO: 1 and SEQ ID NO: 2.